The Food and Drug Administration (FDA) issued a letter to health care providers on December 4, 2001, concerning the medication, droperidol. The purpose of the warning was to alert health care providers to the possible role of droperidol in the development of torsades de pointes (TdP) in susceptible patients. The purpose of this article is to explore the role of droperidol in the development of TdP in susceptible patients and current recommendations for the use of droperidol as an antiemetic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jopan.2006.02.002 | DOI Listing |
Publication Analysis
Top Keywords
health care
8
care providers
8
role droperidol
8
droperidol development
8
tdp susceptible
8
susceptible patients
8
droperidol's interval
4
interval food
4
food drug
4
drug administration
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!